Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3045-3048

  Bogatcheva, Elena ^a   Hanrahan, Colleen ^a   Nikonenko, Boris ^a   Samala, Rowena ^a   Chen, Ping ^a   Gearhart, Jacqueline ^a   Barbosa, Francis ^a   Einck, Leo ^a   Nacy, Carol A ^a   Protopopova, Marina ^a  

^a SEQUELLA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOMETHYLPIPERIDINE; 4 AMINOPHENYLETHYLAMINE; 4,4' METHYLENEBISCYCLOHEXYLAMINE; BENZYLPIPERAZINE; DIAMINE; HEXAHYDRO 1,4 DIAZEPINE; HEXYLAMINE; N GERANYL N' (2 ADAMANTYL)ETHANE 1,2 DIAMINE; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; SQ 109; SQ 775; SQ 786; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROSPECTIVE STUDY; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; COMBINATORIAL CHEMISTRY TECHNIQUES; DIAMINES; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PIPERAZINES; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, PULMONARY;

EID: 33744790912     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050948+     Document Type: Article

References (20)

1. Dye, C.; Scheele, S.; Dolin, P.; Pathania, V.; Raviglione, M. C. Global burden of tuberculosis. J. Am. Med. Assoc. 1999, 282, 677-686.
2. Bass, J. B.; Farer L. S.; Hopewell P. C.; O'Brein, R.; Jacob, R. F.; Ruben, F.; Snider, D. E., Jr.; Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 1994, 149, 1359-1374.
3. Farmer, P.; Bayona, J.; Becerra, M.; Furin, J.; Henry, C.; Hiatt, H.; Kim, J. Y.; Mitnick, C.; Nardell, E.; Shin, S. The dilemma of MDR-TB in the global era. Int. J. Tuberc. Lung Dis. 1998, 2, 869-876.
4. Cohn, D. L.; Bustreo, F.; Raviglione, M. C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin. Infect. Dis. 1997, 24 (Suppl 1), S121-S130.
5. Espinal, M. A.; Laslo, A.; Simonsen, L.; Boulahbal, F.; Kim, S. J.; Reniero, A.; Hoffner, S.; Reider, H. L.; Binkin, N.; Dye, C.; Williams, R.; Raviglione, M. C. Global trends in resistance to antituberculosis drugs (For the World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance). N. Engl. J. Med. 2001, 343, 1294-1303.
6. Stokstad, E. Drug-resistant TB on the rise. Science 2000, 287, 2391.
7. Lee, R. E.; Protopopova, M.; Crooks, E.; Slayden, R. A.; Terrot, M.; Barry, C. E., Ill Combinatorial lead optimization of [1, 2]-diamines based on Ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 2003, 5, 172-187.
8. Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C. A. Identification of a new antitubercular drug candidate SQ109 from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 2005, 56, 968-974.
9. Jia L.; Tomaszewski, J. E.; Hanrahan, C.; L. Coward, L.; P. Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 2005, 144, 80-87.
10. For antitubercular activity of some compound classes enhanced by the piperazine mojety, see the following: Renau, T. E.; Sanchez, J. P.; Gage, J. W.; Dever, J. A.; Shapiro, M. A.; Gracheck, S. J.; Domagala, J. M. J. Med. Chem. 1996, 39, 729-735.
11. Foroumadi, A.; Soltani, F.; Moshafi, M. H. Boll. Chim. Farm. 2002, 141, 394-396.
12. Tangallapally, R. P.; Yendapally R.; Lee, R. E.; Hevener K.; Jones, V. C.; Lenaerts, A. J. M.; McNeil, M. R.; Wang, Y.; Franzblau, S.; Lee, R. E. J. Med. Chem. 2004, 47, 5276-5283.
13. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B.; Staveski, M. M.; Leonard, M.; Gregory, J. S.; Janjigian, A. D.; Yee, C.; Musser, J. M.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W. R., Jr.; Sacchettini, J. C.; Fidock, D. A. J. Biol. Chem. 2003. 278, 20851-20859.
14. Foks, H.; Pancechowska-Ksepko, D.; Janowiec, M.; Zwolska, Z.; Augustynowicz-Kopec, E. Acta Pol. Pharm. 2004, 61, 473-476.
15. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an aqueous tetrazolium/formazan assay for cell growth assay in culture. Cancer Commun. 1991, 3, 207-212.
16. ueous; Non-Radioactive Cell Proliferation Assay Technical Bulletin, Promega Corporation: Madison, WI, 2005.
17. Lipinskii, C. A.; Lombardo, F.; B. W. Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
18. Nikonenko, B. V.; Samala, R.; Einck, L.; Nacy, C. A. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimocrob. Agents Chemother. 2004, 48, 4550-4555.
19. Kelly, B. P.; Furney, S. K.; Jessen, M. T.; Orme, I. M. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1996, 40, 2809-2812.
20. 13 The following reduction in the CFU was observed (compared to a group of infected nontreated mice): 3.5 log (isoniazid); 0.7 log (SQ775); 1.0 log (SQ786).